ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Trial details
- Registry ID
- NCT07007559
- Phase
- Phase 2
The FDA approved Capecitabine (Xeloda) on 30 Apr 1998.
Drug identity checked against registry records
Also recorded as Xeloda; xeloda
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1998-04-30Day | Capecitabine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020896", "applicant_as_listed_by_fda": "CHEPLAPHARM", "brand_names": ["XELODA"], "active_ingredients": ["CAPECITABINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19980430", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |